HalozymeHALO
HALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 373
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
122% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 41
82% more call options, than puts
Call options by funds: $23.1M | Put options by funds: $12.7M
10% more funds holding
Funds holding: 456 [Q2] → 500 (+44) [Q3]
10% more capital invested
Capital invested by funds: $6.63B [Q2] → $7.26B (+$636M) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 166
0.8% more ownership
Funds ownership: 99.44% [Q2] → 100.24% (+0.8%) [Q3]
55% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 5 (-6) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$53
8%
downside
Avg. target
$60
5%
upside
High target
$70
22%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 32% 1-year accuracy 54 / 171 met price target | 22%upside $70 | Buy Reiterated | 4 Feb 2025 |
Wells Fargo Mohit Bansal 52% 1-year accuracy 12 / 23 met price target | 1%downside $57 | Equal-Weight Maintained | 13 Jan 2025 |
Piper Sandler Joseph Catanzaro 34% 1-year accuracy 11 / 32 met price target | 8%downside $53 | Neutral Maintained | 10 Jan 2025 |
Financial journalist opinion
Based on 8 articles about HALO published over the past 30 days
Positive
Investors Business Daily
6 days ago
Halozyme Stock Climbs Back After 2024 Sneak Peak As Earnings Loom
This biotech stock is recovering from a severe drop in November after the company raised its 2025 guidance. The post Halozyme Stock Climbs Back After 2024 Sneak Peak As Earnings Loom appeared first on Investor's Business Daily.
Neutral
PRNewsWire
1 week ago
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m.
Neutral
PRNewsWire
1 week ago
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy. "We are pleased that the subcutaneous formulation of amivantamab, which was developed with our ENHANZE drug delivery technology, was recommended for approval in Europe," said Dr. Helen Torley, president and chief executive officer of Halozyme.
Positive
Zacks Investment Research
1 week ago
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
2 weeks ago
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
2 weeks ago
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
Investors Business Daily
2 weeks ago
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Zacks Investment Research
4 weeks ago
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
Positive
Zacks Investment Research
1 month ago
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Positive
Zacks Investment Research
1 month ago
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
Charts implemented using Lightweight Charts™